ArticleDermatology and therapy2025

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE.

Jonathan I Silverberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.